Related Experiment Video

Updated: Jun 5, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

Eduardo Vilar1, Jose Perez-Garcia, Josep Tabernero

  • 1Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical Center, C369 Med Inn Bldg, 1500 E. Medical Center Dr., Ann Arbor, MI, USA. evilar@umich.edu

Molecular Cancer Therapeutics
|January 11, 2011
PubMed

Insights

Newer phosphatidylinositol-3-kinase (PI3K)/mTOR inhibitors target both mTOR complex 1 and 2. This advancement stems from a deeper understanding of the PI3K/mTOR pathway, improving cancer treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol-3-kinase (PI3K)/mTOR pathway is crucial in cancer research.
  • Early understanding limited the development of mTOR inhibitors and biomarkers.
  • Recent research highlights the dual nature of mTOR complexes (mTORC1 and mTORC2).

Purpose of the Study:

  • To review recent insights into mTOR pathway signaling.
  • To focus on the development of novel mTOR inhibitors.
  • To discuss the implications for cancer therapy.

Main Methods:

  • Review of current scientific literature on PI3K/mTOR pathway signaling.
  • Analysis of the development and mechanisms of second-generation mTOR inhibitors.
  • Examination of biomarker strategies for patient selection.

Main Results:

  • A more profound understanding of mTOR complex regulation and feedback loops has emerged.
  • Second-generation inhibitors targeting both mTORC1 and mTORC2 have been developed.
  • Some new inhibitors also target PI3K, addressing feedback mechanisms.

Conclusions:

  • Deeper insights into the PI3K/mTOR pathway facilitate the development of advanced cancer therapeutics.
  • Next-generation mTOR inhibitors offer improved efficacy by targeting both mTOR complexes.
  • Targeting PI3K alongside mTOR may overcome resistance mechanisms.

More Related Videos

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...